TrialAmerican journal of hematology2017

A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral T-cell lymphomas.

Philip S Boonstra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.